Bausch Health Reports Strong Q2 Earnings, Drives Stock Surge
Bausch Health (NYSE:BHC) saw its stock rise by 28.85% to $6.03 per share following a strong second-quarter performance that marked significant progress in the company's turnaround efforts. The pharmaceutical firm reported a net income of $260 million for Q2, up from $128 million during the same period last year and reversing its previous quarter’s loss. Revenue increased by 12.7% to $2.85 billion, driven primarily by strong sales in key segments like Salix (+21%), International (+10%), and Solta Medical (+38%). Encouraged by these results, Bausch Health raised its full-year revenue guidance to between $10.79 billion and $11.04 billion from the earlier range of $10.67 billion to $10.92 billion. The company also increased its adjusted EBITDA forecast to $4.05 billion–$4.175 billion, up from previous guidance. Despite these positive developments, institutional investor participation in Bausch Health declined during the first quarter of 2026, with hedge fund holdings dropping by 24.4% to $732.9 million.
Tickers: $BHC
Topics: financial_performance pharmaceuticals profitability revenue_growth